



PRESS RELEASE

BSE: 506690

NSE: UNICHEMLAB

Reuters: UNLB.BO

Bloomberg: UN@IN

Mumbai, August 27, 2009

Unichem Laboratories receives ANDA approval from USFDA for CLONIDINE HYDROCHLORIDE TABLETS

Unichem laboratories Limited are pleased to announce that it has received ANDA approval from the United States Food and Drug Administration (U.S. FDA) for Clonidine Hydrochloride Tablets.

Clonidine Hydrochloride Tablets USP 0.1mg, 0.2mg and 0.3mg are therapeutically equivalent to CATAPRES® Tablets USP 0.1mg, 0.2mg and 0.3mg from Boehringer Ingelheim. Clonidine Hydrochloride formulations have annual sales of approximately USD 334 million in the US.

Clonidine Hydrochloride is a low dose potent and popular molecule in the antihypertensive category.

The product will be now immediately commercialized from Unichem's Goa plant. Active pharmaceutical ingredient i.e. Clonidine Hydrochloride used for this ANDA is also made in house at Roha plant. **This ANDA** approval will substantially increase the presence of Unichem in US market. Unichem already has 6 other ANDA's duly approved and there are some more ANDA's in pipeline.

About Unichem Laboratories Limited.

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, orthopedics and anti-infectives. The company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms. More information about the company can be found at www.unichemindia.com.

Contacts:

Mr. K Subharaman

Tel: +912266888404

Cell: +919833031121

e-Mail: subharamank@unichemindia.com

Mr. Rakesh Parikh

Tel: +912266888414

Cell: +919892925555

e-Mail: rparikh@unichemindia.com

Mr. M Gundu Rao

Tel: +912266888380

Cell: +919820228944

e-Mail: gundurao@unichemindia.com

This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

-oOo-